FcRn inhibitors: a novel option for the treatment of myasthenia gravis
Li-Na Zhu
Hai-Man Hou
Sai Wang
Shuang Zhang
Ge-Ge Wang
Zi-Yan Guo
Jun Wu
Department of Neurology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan Province,China
摘要：Myasthenia gravis is an acquired, humoral immunity-mediated autoimmune disease characterized by the production of autoantibodies that impair synaptic transmission at the neuromuscularjunction. The intervention-mediated clearance of immunoglobulin G (IgG) was shown to be effective in controlling the progression of the disease. The neonatal Fc receptor (FcRn) plays a key role in prolonging the serum half-life of IgG. Antagonizing FcRn to prevent its binding to IgG can accelerate the catabolism of the latter, resulting in decreased levels of IgG, including pathogenic autoantibodies, thereby achieving a therapeutic effect. In this review, we detail the substantial research progress, both basic and clinical, relating to the use of FcRn inhibitors in the treatment of myasthenia gravis.
机标关键词：inhibitorsoptionnovelfcrngravismyastheniatreatment
论文发表日期：2023-08-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：8( 1637-1644 )
英文信息